journal article·1985-05

Potential and limitations of drug targeting: An overview

Colin R. Gardner

Biomaterials· Volume 6· Issue 3
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Computational Drug Discovery Methods · Pharmacogenetics and Drug Metabolism · Cholinesterase and Neurodegenerative Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (55)

Show source-provided references
1. Methods to achieve controlled drug delivery—the biomedical engineering approach
2. Suzuki, Y., Ikura, H., Yamashita, G. and Nagai, T., French patent, FR 2497098, 1982
3. The role of esterase activity in the ocular disposition of dipivaloyl epinephrine in rabbits10.1016/0378-5173(83)90041-8 ↗
4. Enhanced percutaneous penetration with 1-dodecylazacycloheptan-2-one10.1001/archderm.1982.01650190028013 ↗
5. Multimodality cancer therapy in man: A pilot study of adriamcyin by arterial infusion10.1002/1097-0142(197406)33:6<1485::AID-CNCR2820330602>3.0.CO;2-V ↗
6. Pratt · 1977
7. Inhibitor binding analysis of dihydrofolate-reductases from various species10.1016/S0026-895X(25)14734-2 ↗
8. Comparative biochemistry of dihydrofolate reductase10.1111/j.1749-6632.1971.tb31136.x ↗
9. Principles of Biochemistry
10. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl) guanine10.1016/S0021-9258(17)34236-9 ↗
11. The carrier potential of liposomes in biology and medicine10.1056/NEJM197609232951305 ↗
12. The carrier potential of liposomes in biology and medicine10.1056/NEJM197609302951406 ↗
13. New aspects of liposomes10.1016/0304-4157(76)90002-2 ↗
14. Selectivity in cancer chemotherapy
15. Site-specific (targeted) drug delivery in cancer therapy10.1038/nbt1283-869 ↗
16. Radiopharmaceutical targeting in nuclear medicine
17. Suspensions of radioalbumin aggregates for photoscanning the liver, spleen, lung and other organs
18. Chemotheraphy through liposomes with a DNA-daunorubicin complex
19. Fate of a liposome-entrapped agent injected into normal and tumourbearing rodents. Attempts to improve localization in tumour tissues10.1016/0024-3205(77)90516-1 ↗
20. Treatment of tumourbearing mice with liposome-entrapped actinomycin D prolongs their survival
21. Liposomes-further considerations of their possible role as carriers of therapeutic agents
22. Lenk · 1983
23. Dapergolas · Lancet · 1976 · ii · 82410.1016/S0140-6736(76)91209-5 ↗
24. Harding · Biochem. Soc. Trans. · 1978 · 6 · 78410.1042/bst0061248 ↗
25. Lipid vesicles as carriers for introducing drugs and other biologically active materials into cells. II. In vivo systems10.1111/j.1749-6632.1978.tb22031.x ↗
26. The preoperative detection of axilliary lymph node metastases in breast cancer by isotope imaging10.1002/bjs.1800700303 ↗
27. Liposomes as steroid carriers in the intra-articular therapy of rheumatoid arthritis
28. Phase transition release, a new approach to the interaction of proteins with lipid vesicles. Application to lipoproteins10.1016/0005-2736(81)90255-8 ↗
29. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumour agents10.1016/S1054-3589(08)60246-X ↗
30. The effect of particle size and charge on the clearance rates of liposomes and liposome-encapsulated drugs10.1016/S0006-291X(75)80433-5 ↗
31. Monoclonal antibodies for the targeting of drugs: application to nanoparticles
32. Pharmacokinetics and distribution of a biodegradable drug-carrier10.1016/0378-5173(83)90166-7 ↗
33. Therapeutic potential of liposomes as carriers in Leishmaniasis, malaria and vaccines
34. Controlled release from glycosaminoglycan drug complexes
35. Cell-specific ligands for selective drug delivery to tissues and organs10.1021/jm00144a004 ↗
36. Targeting of radionuclides and drugs for the diagnosis and treatment of cancer
37. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells
38. Antibody-mediated targeting of liposomes. Binding to lymphocytes does not ensure incorporation of vesicle contents into the cells10.1016/0005-2736(78)90047-0 ↗
39. Pro-drugs: an overview and definition
40. Pro-drugs and site-specific delivery10.1021/jm00186a001 ↗
41. Critique of pro-drugs and sitespecific drug delivery
42. Sinemet and the treatment of Parkinsonism10.7326/0003-4819-94-3-364 ↗
43. γ-glutamyl dopa: a kidney-specific dopamine precursor10.1016/S0022-3565(25)31317-0 ↗
44. Plasmin-activated pro-drugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard10.1021/jm00359a003 ↗
45. Delivery of a quaternary pyridinium salt across the blood-brain barrier by its dihydropyridine derivative10.1126/science.1166305 ↗
46. Improved delivery through biological membranes. XV. Sustained brain delivery of berberine
47. Redox delivery system for brainspecific, selective release of dopamine10.1126/science.6857264 ↗
48. Chemistry and enzymology of kcat inhibitors10.1126/science.185.4148.320 ↗
49. 1979
50. Inhibition of aromatic amino acid decarboxylase and depletion of biogenic amines in brain of rats treated with alphamonofluoromethyl p-tyrosine: similitudes and differences with the effects of alpha-monofluoromethyldopa10.1016/0006-2952(84)90493-3 ↗
51. MDL72394, a site-selective inhibitor of monoamine oxidase (MAO)
52. Substrate-selective monoamine oxidases — inhibitor tissue, species and functional differences10.1016/0006-2952(78)90001-1 ↗
53. Receptor-binding profile of R41468, a novel antagonist at 5HT2 receptors10.1016/0024-3205(81)90747-5 ↗
54. Brain dopamine receptors10.1016/S0031-6997(25)06839-5 ↗
55. (-) Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor10.1038/283092a0 ↗